Home » News and Development » UK. CBD anti-epilepsy medicine planned by GW Pharmaceuticals

UK. CBD anti-epilepsy medicine planned by GW Pharmaceuticals


sativex bottle


GW Pharmaceuticals may be best known for their Sativex oral spray which gives a 1:1 ratio of THC:CBD.  THC and CBD are 2 of the many cannabinoid chemicals found in cannabis.  Their new drug is codenamed, interestingly,  GWP420 006, and is in phase-1 clinical trials, and has been in development for several years. 

GW Pharma claim this is a non-pyschoactive medicine, suggesting a possible THC-free formula (or a very low THC formula).  Initial results are encouraging, and GW Pharmaceuticals are highly likely to eventually commercialise this new product once all clinical trials have been completed.  Many cannabis users will already be aware of cannabis as an effective medicine for seizures, it will be interesting to see the future peer-reviewed data from the phase-2  and phase-3 trials.

More information can be read on the GW Pharmaceuticals website https://www.gwpharm.com/Phase1Epilepsy.aspx


October 29th 2013

Related items

Recent comments (0)

Leave a comment

Your comment
Type the characters you see in the picture below
I would like to receive the newsletter
Contact   |   Disclaimer   |   Privacy policy, terms and conditions

Dutch Passion advise their customers to reassure themselves of local applicable laws and regulations before germination. Dutch Passion cannot be held responsible for the actions of those who act against laws and regulations that apply in their locality. Cannabis seeds should be kept as collectible souvenirs by anyone in an area where cultivation of cannabis is not legal.